Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 8/20 | 0.67 |
| ▸ | S1PR4 known ✓ | O95977 | 7/20 | 0.64 |
| ▸ | S1PR3 known ✓ | Q99500 | 6/20 | 0.64 |
| ▸ | S1PR5 known ✓ | Q9H228 | 5/20 | 0.64 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.53 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.53 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.53 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.53 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.53 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.53 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.53 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.53 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8498597 | 0.98 | S1PR1 (0.66) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL8498533 | 0.98 | S1PR1 (0.66) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL26881637 | 0.98 | S1PR1 (0.66) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL8495721 | 0.98 | S1PR1 (0.66) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL8500217 | 0.98 | S1PR1 (0.66) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL25703818 | 0.84 | HTR2A (0.58) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL13165347 | 0.83 | S1PR1 (0.54) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL25371922 | 0.81 | S1PR1 (0.52) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8498778 | 0.80 | S1PR1 (1.00) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8499671 | 0.80 | S1PR1 (0.88) | S1PR1S1PR4S1PR3TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270696-A1 | MEDICINAL USE OF FINGOLIMOD IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS | CHEN DAN (CN) | 2023-08-31 | — | — | US | claimed |
| WO-2022095610-A1 | MEDICINAL USE OF FINGOLIMOD IN PREVENTING AND TREATING NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS | 杭州端丽生物技术有限公司 | 2022-05-12 | — | — | WO | claimed |
| CN-119424398-A | Application of fingolimod in preparation of medicine for treating hepatolenticular degeneration | 上海交通大学医学院附属新华医院 | 2025-02-14 | — | — | CN | disclosed |
| CN-117379407-A | Application of fingolimod in preparation of medicine for treating acute myelogenous leukemia | 北京大学人民医院 | 2024-01-12 | — | — | CN | disclosed |
| US-20230270696-A1 | MEDICINAL USE OF FINGOLIMOD IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS | CHEN DAN (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-114796180-A | Use of myriocin and fingolimod in inhibiting candida auriculata | 复旦大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022095610-A1 | MEDICINAL USE OF FINGOLIMOD IN PREVENTING AND TREATING NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS | 杭州端丽生物技术有限公司 | 2022-05-12 | — | — | WO | disclosed |
| CN-112237575-A | Medical application of fingolimod in preventing and treating neurodegenerative diseases caused by sphingolipid disorder | 杭州端丽生物技术有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-111455019-A | Application of compound FTY720 in preparation of detection marker for treating behavioral and movement abnormalities | 杭州端丽生物技术有限公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-108642129-A | Medical application of impulse control disorder biological detection marker and Impulse sin | 杭州端丽生物技术有限公司 | 2018-10-12 | — | — | CN | disclosed |